All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
JZP458 in ALL/LBL: Post hoc analysis from AALL1931 trial
|
Results from the post hoc analysis of the ALL1931 trial (NCT04145531) of JZP458 in children and adult patients with acute lymphoblastic leukemia (ALL) or lymphoblastic leukemia who had developed sensitivity to Escherichia coli-derived asparaginases were presented during the European Hematology Association (EHA) 2024 Hybrid Congress by Maese.1 The analysis evaluated different doses of JZP458 in two cohorts (intramuscular [IM] and intravenous [IV] cohorts) of 112 patients and reported on adverse events (AEs) of interest and nausea/vomiting.1 |
| Key learnings |
| The frequency of any-grade treatment-related allergic reactions was 11% and 26% in the IM cohort and IV cohorts, respectively. |
| Increase in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) was 16% and 18% in the IM cohort and IV cohorts, respectively. |
| Treatment-related Grade ≥2 nausea/vomiting events was 21% and 61% in the IM cohort and IV cohorts, respectively. |
|
Grade ≥2 nausea/vomiting events in the IM and IV cohorts were:
|
| Any-grade treatment-related allergic reactions, pancreatitis, thrombosis, increased ALT/AST, and increased bilirubin was similar across age groups and between the Hispanic patients (n = 74) and non-Hispanic patients (n = 140). |
| The safety data from this post hoc analysis of the ALL1931 trial support the use of JZP458 in patients with ALL/LBL who are hypersensitive to Escherichia coli-derived asparaginases. |
- Maese L. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interests from AALL1931. Poster #P407. Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16, 2024; Madrid, ES.
More about...
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox